General Information of Drug (ID: DMNAT5V)

Drug Name
GW-2592X Drug Info
Synonyms
Azepanone inhibitors, GlaxoSmithKline; Cathepsin K inhibitors (bone disorder); Cathepsin K inhibitors, SmithKline Beecham; GW-2637X; GW-2934X; GW-9696X; SB-237632; SB-244875; SB-267320; SB-271194; SB-327537; SB-331750; SB-357114; SB-432238; SB-553484; Cathepsin K inhibitors (bone disorder), GlaxoSmithKline
Indication
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Preclinical [1]
Bone disease FC0Z Investigative [2]
Cross-matching ID
TTD Drug ID
DMNAT5V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [3]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [4]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [5]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [6]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [6]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [6]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [7]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [6]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [6]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [2]

References

1 Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
3 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
4 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
5 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
6 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
7 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.